Key result
Pacemaker therapy cuts syncope recurrence ~63% versus control in patients with recurrent vasovagal syncope.
Why the study?
Pacemaker therapy with rate drop response or closed-loop stimulation algorithms has been studied in recurrent cardioinhibitory vasovagal syncope with conflicting results.
Does pacemaker therapy reduce syncope recurrence in patients with recurrent cardioinhibitory vasovagal syncope?
Systematic Review (n=228)
Does pacemaker therapy reduce syncope recurrence in patients with recurrent cardioinhibitory vasovagal syncope?
Relative Risk: 0.37 (95% CI 0.14–0.98)
In patients with recurrent cardioinhibitory vasovagal syncope, pacemaker therapy with closed-loop stimulation (CLS) significantly reduces syncope recurrence, whereas rate drop response (RDR) pacing does not.
Pacing benefit in cardioinhibitory VVS remains uncertain after blinded trials; CLS algorithms merit targeted prospective evaluation.
Vasovagal reflex is the most common cause of syncope. Pacemaker with rate drop response (RDR) or closed‐loop stimulation (CLS) anti‐syncope algorithms have been studied in recurrent vasovagal syncope (VVS), with conflicting results. We aim to investigate the role of pacemaker therapy and anti‐syncope pacing mode in cardioinhibitory recurrent VVS. MEDLINE, Cochrane Library and registered clinical trials were searched for single or double‐blind randomized controlled trials on pacing as a treatment for recurrent VVS. Five studies were eligible, overall enrolling 228 patients. After pooling data from all trials, pacemaker therapy showed a 63% reduction in syncope recurrence compared to control [Risk Ratio (RR): 0.37; 95% CI: 0.14‐0.98; I2 = 67%)]. Subgroup analyses suggested that the effect was greater in single‐blind studies (RR: 0.07; 95% CI: 0.01‐0.52, I2 = 0%). When comparing pacing algorithms, the results from RDR versus no pacing trials (n = 2) did not show a significant reduction in syncope recurrence (RR: 0.73; 95% CI: 0.25‐2.16, I2 60 = 75%). In contrast, the data from the CLS versus standard pacing trials (n = 3) evidenced a statistically meaningful reduction in syncopal burden (RR: 0.18; 95% CI: 0.07‐0.47, I2 = 0%). It is unclear whether pacemaker therapy reduces syncopal burden in cardioinhibitory recurrent VVS. However, our results suggest effectiveness of CLS pacing mode.
No takes yet. Share an insight, caveat, or question.
Cunha et al. (2019) conducted a systematic review in cardioinhibitory recurrent vasovagal syncope (n=228). Pacemaker therapy vs. control was evaluated on syncope recurrence (RR 0.37, 95% CI 0.14-0.98). Pacemaker therapy reduced syncope recurrence by 63% compared to control in patients with recurrent vasovagal syncope (RR 0.37; 95% CI 0.14-0.98).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: